InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (3 ops.)
Browse the detailed record of transactions filed by New Enterprise Associates 16, L.P.. Director active across 3 companies, notably Trevi Therapeutics, Inc.. Aggregated, 6 filings have been recorded. Total volume traded: €5m. The latest transaction was disclosed on 24 May 2022 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations6 total
€361,3305,931,843 shares@ €0.0609100.0% of flow
Common Stock
SEC:0001209191-22-032327:0·
€5m2,631,578 shares@ €1.74670.23% mcap100.0% of flow
Common Stock
SEC:0001209191-22-024301:0·
Ideal exit: 6 Jan 2023 (T+270)
€43,94637,570 shares@ €1.1697100.0% of flow
Common Stock
SEC:0001209191-21-071265·
€43,94637,570 shares@ €1.169750.0% of flow
Common Stock
SEC:0001209191-21-071265:0·
1,851,852 shares
Common Stock
SEC:0001209191-21-061090·
Ideal exit: 15 Jul 2022 (T+270)
1,851,852 shares
Common Stock
SEC:0001209191-21-061090:0·
Ideal exit: 15 Jul 2022 (T+270)
6 of 6 declarations
About New Enterprise Associates 16, L.P.
New Enterprise Associates 16, L.P. is a director and insider at Trevi Therapeutics, Inc., Metacrine, Inc., and Genocea Biosciences, INC.
